Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Bromodomain and extraterminal domain (BET) family member BRD4 is a cancer target.
• Existing BRD4 inhibitors show limited efficacy due to protein accumulation.
• MYC-driven malignancies like Burkitt's lymphoma (BL) are potential therapeutic areas.

Purpose of the Study:

• To overcome limitations of traditional BRD4 inhibitors.
• To evaluate the efficacy of a novel hetero-bifunctional proteolysis targeting chimera (PROTAC) in targeting BRD4.
• To investigate ARV-825's mechanism and effectiveness in BL.

Main Methods:

• Design and synthesis of ARV-825, a BRD4-targeting PROTAC.
• Treatment of BL cell lines with ARV-825 and small-molecule BRD4 inhibitors.
• Assessment of BRD4 protein levels, MYC expression, downstream signaling, cell proliferation, and apoptosis.

Main Results:

• ARV-825 induced rapid, efficient, and sustained BRD4 degradation in BL cells.
• ARV-825 demonstrated superior suppression of c-MYC and downstream signaling compared to traditional inhibitors.
• ARV-825 achieved more effective inhibition of proliferation and induction of apoptosis in BL.

Conclusions:

• Hetero-bifunctional PROTACs offer a superior strategy for targeting BRD4 compared to small-molecule inhibitors.
• ARV-825 represents a promising therapeutic approach for BRD4-driven cancers.
• Cereblon-based PROTACs provide enhanced efficacy in targeting BRD4.